TCGA-AC-A3QP-01A-11R-A22U-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 22
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.370
- MYOGENESIS+0.350
- OXIDATIVE_PHOSPHORYLATION+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- PANCREAS_BETA_CELLS+0.290
- ANGIOGENESIS+0.280
- ALLOGRAFT_REJECTION+0.250
- P53_PATHWAY+0.230
- KRAS_SIGNALING_DN+0.210
- XENOBIOTIC_METABOLISM+0.210
Top 10 suppressed
- G2M_CHECKPOINT-0.640
- E2F_TARGETS-0.630
- MITOTIC_SPINDLE-0.550
- PROTEIN_SECRETION-0.530
- MTORC1_SIGNALING-0.380
- PI3K_AKT_MTOR_SIGNALING-0.350
- ANDROGEN_RESPONSE-0.330
- UV_RESPONSE_DN-0.320
- TGF_BETA_SIGNALING-0.280
- INTERFERON_ALPHA_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-Z7-A8R5-01A-42R-A41B-07 | — | B | 0.916 |
| 2 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.891 |
| 3 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.875 |
| 4 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.873 |
| 5 | TCGA-WT-AB44-01A-11R-A41B-07 | — | B | 0.867 |
| 6 | TCGA-LD-A66U-01A-11R-A31O-07 | — | B | 0.864 |
| 7 | TCGA-BH-A42U-01A-12R-A24H-07 | — | B | 0.841 |
| 8 | TCGA-E2-A1IF-01A-11R-A144-07 | — | A | 0.832 |
| 9 | SJEPD028_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.831 |
| 10 | MNG1103 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |